

Peru

Region of the Americas




I. Epidemiological profile

Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	3,420,000	11	Plasmodium species: <i>P. falciparum</i> (21%), <i>P. vivax</i> (79%)
Low transmission (0-1 cases per 1000 population)	1,020,000	3	Major anopheles species: <i>An. pseudopunctipennis</i> , <i>An. albimanus</i> , <i>An. darlingi</i>
Malaria-free (0 cases)	26,900,000	86	Reported confirmed cases (health facility): 66,609 Estimated cases: 150,000 [120,000 ; 180,000]
Total	31,380,000		Confirmed cases at community level: - Reported deaths: 3 Estimated deaths: <10


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted						
ITN	ITNs/ LLINs distributed free of charge	Yes	-	First-line treatment of unconfirmed malaria	-	-						
	ITNs/ LLINs distributed to all age groups	Yes	-	First-line treatment of <i>P. falciparum</i>	AS+MQ	2001						
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	-	-						
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS+MQ	-						
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	CQ+PQ	-						
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.50 mg/Kg (7 days)						
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type pf RDT used		-						
	Malaria diagnosis is free of charge in the public sector	Yes	-									
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)								
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species	
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-	AS+MQ	2005-2006	1.1	1.1	1.1	28 days	1	<i>P. falciparum</i>	
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	CQ+PQ	2006-2008	0.5	0.6	1.1	28 days	3	<i>P. vivax</i>	
	G6PD test is a requirement before treatment with primaquine	No	-									
	Directly observed treatment with primaquine is undertaken	Yes	-									
	System for monitoring adverse reactions to antimalarials exists	Yes	-									
Surveillance	ACD for case investigation (reactive)	Yes	-	Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)								
	ACD of febrile cases at community level (pro-active)	Yes	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested			
	Mass screening is undertaken	Yes	-	2013	Yes				An. albimanus, An. darlingi			
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-									
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-									
	Foci and case investigation undertaken	-	-									
Case reporting from private sector is mandatory	Yes	-										


III. Financing




Government expenditure by intervention in 2015




IV. Coverage




Cases tested and treated in public sector




V. Impact



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

